Novo Nordisk will sell its blockbuster weight-loss drug Wegovy for under half its normal price via a new direct-to-consumer online pharmacy.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Now that semaglutide’s no longer in shortage territory, the FDA said drug-makers have 90 days to wrap up production of their Novo knockoffs.
It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.